Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02985398 · ClinicalTrials.gov registry record · Phase 3
An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine
A Phase 3 study, sponsored by Alder Biopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 128
- Enrollment target
NCT02985398 is a Phase 3 study that has completed, run by Alder Biopharmaceuticals. The registered enrollment target is 128 participants.
The verdict
NCT02985398, a Phase 3 study, has completed, sponsored by Alder Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 128 participants
- Enrollment target
Study Summary
An evaluation of long term safety of repeat ALD403 doses in Chronic Migraine
Interventions
- BIOLOGICAL ALD403 (Eptinezumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2016-12 |
| Est. Completion | 2019-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02985398
The ClinicalTrials.gov registry entry for NCT02985398 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alder Biopharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALD403 (Eptinezumab) is the first listed.
NCT02985398 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02985398 about?
NCT02985398 is a clinical study titled "An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine". An evaluation of long term safety of repeat ALD403 doses in Chronic Migraine
What is the current status of trial NCT02985398?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 128 participants. The study started on 2016-12. Estimated completion is 2019-03.
What interventions are being tested in trial NCT02985398?
The interventions under investigation include: ALD403 (Eptinezumab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02985398?
This trial is sponsored by Alder Biopharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.